As biology becomes an engineering discipline, the way companies are funded is evolving just as quickly. From AI-native biotech startups to capital-intensive biomanufacturing platforms, investors are rethinking how to underwrite risk, structure deals, and support companies from inception to scale. This panel brings together leading investors across venture, crossover, and strategic capital to explore how funding models are adapting to the realities of programmable biology. What makes a compelling company today? How are timelines, capital efficiency, and technical milestones being reframed? And where are the biggest opportunities emerging across human health, climate, and industrial biotech?

As biology becomes programmable and AI accelerates discovery, startups are generating breakthrough innovations at unprecedented speed. Yet translating these advances into real-world therapies still depends on effective collaboration with global pharmaceutical organizations. This session explores how the innovation ecosystem connects early-stage breakthroughs to scalable development, bringing together leaders from startup incubation, external innovation, and pharma strategy. Speakers will examine how AI-native biotech companies engage with pharma today: how startups become “pharma-ready,” how external innovation teams evaluate and structure partnerships, and what collaboration models are emerging as biology and computation converge. From early ecosystem support and venture building to strategic alliances and co-development pathways, the discussion will provide a practical look at how ideas move from discovery to patient impact in the AI era.